Prolactin and oxytocin: potential targets for migraine treatment
Abstract Migraine is a severe neurovascular disorder of which the pathophysiology is not yet fully understood. Besides the role of inflammatory mediators that interact with the trigeminovascular system, cyclic fluctuations in sex steroid hormones are involved in the sex dimorphism of migraine attack...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | The Journal of Headache and Pain |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s10194-023-01557-6 |
| _version_ | 1797853660020998144 |
|---|---|
| author | Anna K. Szewczyk Samiye Ulutas Tülin Aktürk Linda Al-Hassany Corinna Börner Federica Cernigliaro Michalis Kodounis Salvatore Lo Cascio David Mikolajek Dilara Onan Chiara Ragaglini Susanna Ratti Eduardo Rivera-Mancilla Sofia Tsanoula Rafael Villino Karl Messlinger Antoinette Maassen Van Den Brink Tessa de Vries on behalf of the European Headache Federation School of Advanced Studies (EHF-SAS) |
| author_facet | Anna K. Szewczyk Samiye Ulutas Tülin Aktürk Linda Al-Hassany Corinna Börner Federica Cernigliaro Michalis Kodounis Salvatore Lo Cascio David Mikolajek Dilara Onan Chiara Ragaglini Susanna Ratti Eduardo Rivera-Mancilla Sofia Tsanoula Rafael Villino Karl Messlinger Antoinette Maassen Van Den Brink Tessa de Vries on behalf of the European Headache Federation School of Advanced Studies (EHF-SAS) |
| author_sort | Anna K. Szewczyk |
| collection | DOAJ |
| description | Abstract Migraine is a severe neurovascular disorder of which the pathophysiology is not yet fully understood. Besides the role of inflammatory mediators that interact with the trigeminovascular system, cyclic fluctuations in sex steroid hormones are involved in the sex dimorphism of migraine attacks. In addition, the pituitary-derived hormone prolactin and the hypothalamic neuropeptide oxytocin have been reported to play a modulating role in migraine and contribute to its sex-dependent differences. The current narrative review explores the relationship between these two hormones and the pathophysiology of migraine. We describe the physiological role of prolactin and oxytocin, its relationship to migraine and pain, and potential therapies targeting these hormones or their receptors. In summary, oxytocin and prolactin are involved in nociception in opposite ways. Both operate at peripheral and central levels, however, prolactin has a pronociceptive effect, while oxytocin appears to have an antinociceptive effect. Therefore, migraine treatment targeting prolactin should aim to block its effects using prolactin receptor antagonists or monoclonal antibodies specifically acting at migraine-pain related structures. This action should be local in order to avoid a decrease in prolactin levels throughout the body and associated adverse effects. In contrast, treatment targeting oxytocin should enhance its signalling and antinociceptive effects, for example using intranasal administration of oxytocin, or possibly other oxytocin receptor agonists. Interestingly, the prolactin receptor and oxytocin receptor are co-localized with estrogen receptors as well as calcitonin gene-related peptide and its receptor, providing a positive perspective on the possibilities for an adequate pharmacological treatment of these nociceptive pathways. Nevertheless, many questions remain to be answered. More particularly, there is insufficient data on the role of sex hormones in men and the correct dosing according to sex differences, hormonal changes and comorbidities. The above remains a major challenge for future development. |
| first_indexed | 2024-04-09T19:54:15Z |
| format | Article |
| id | doaj.art-800eed8f73924606a2775bdd8d3111ba |
| institution | Directory Open Access Journal |
| issn | 1129-2377 |
| language | English |
| last_indexed | 2024-04-09T19:54:15Z |
| publishDate | 2023-03-01 |
| publisher | BMC |
| record_format | Article |
| series | The Journal of Headache and Pain |
| spelling | doaj.art-800eed8f73924606a2775bdd8d3111ba2023-04-03T05:34:37ZengBMCThe Journal of Headache and Pain1129-23772023-03-0124112610.1186/s10194-023-01557-6Prolactin and oxytocin: potential targets for migraine treatmentAnna K. Szewczyk0Samiye Ulutas1Tülin Aktürk2Linda Al-Hassany3Corinna Börner4Federica Cernigliaro5Michalis Kodounis6Salvatore Lo Cascio7David Mikolajek8Dilara Onan9Chiara Ragaglini10Susanna Ratti11Eduardo Rivera-Mancilla12Sofia Tsanoula13Rafael Villino14Karl Messlinger15Antoinette Maassen Van Den Brink16Tessa de Vries17on behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)Doctoral School, Medical University of LublinDepartment of Neurology, Kartal Dr. Lutfi Kirdar Research and Training HospitalDepartment of Neurology, Kartal Dr. Lutfi Kirdar Research and Training HospitalDivision of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical CenterDepartment of Pediatrics – Dr. von Hauner Children’s Hospital, LMU Hospital, Division of Pediatric Neurology and Developmental Medicine, Ludwig-Maximilians Universität MünchenChild Neuropsychiatry Unit Department, Pro.M.I.S.E. ”G D’Alessandro, University of PalermoFirst Department of Neurology, Eginition Hospital, National and Kapodistrian University of AthensChild Neuropsychiatry Unit Department, Pro.M.I.S.E. ”G D’Alessandro, University of PalermoDepartment of Neurology, City Hospital OstravaSpine Health Unit, Faculty of Physical Therapy and Rehabilitation, Hacettepe UniversityNeuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’AquilaNeuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’AquilaDivision of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical CenterDepartment of Neurology, 401 Military Hospital of AthensDepartment of Neurology, Clínica Universidad de NavarraInstitute of Physiology and Pathophysiology, Friedrich-Alexander-Universität Erlangen-NürnbergDivision of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical CenterDivision of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical CenterAbstract Migraine is a severe neurovascular disorder of which the pathophysiology is not yet fully understood. Besides the role of inflammatory mediators that interact with the trigeminovascular system, cyclic fluctuations in sex steroid hormones are involved in the sex dimorphism of migraine attacks. In addition, the pituitary-derived hormone prolactin and the hypothalamic neuropeptide oxytocin have been reported to play a modulating role in migraine and contribute to its sex-dependent differences. The current narrative review explores the relationship between these two hormones and the pathophysiology of migraine. We describe the physiological role of prolactin and oxytocin, its relationship to migraine and pain, and potential therapies targeting these hormones or their receptors. In summary, oxytocin and prolactin are involved in nociception in opposite ways. Both operate at peripheral and central levels, however, prolactin has a pronociceptive effect, while oxytocin appears to have an antinociceptive effect. Therefore, migraine treatment targeting prolactin should aim to block its effects using prolactin receptor antagonists or monoclonal antibodies specifically acting at migraine-pain related structures. This action should be local in order to avoid a decrease in prolactin levels throughout the body and associated adverse effects. In contrast, treatment targeting oxytocin should enhance its signalling and antinociceptive effects, for example using intranasal administration of oxytocin, or possibly other oxytocin receptor agonists. Interestingly, the prolactin receptor and oxytocin receptor are co-localized with estrogen receptors as well as calcitonin gene-related peptide and its receptor, providing a positive perspective on the possibilities for an adequate pharmacological treatment of these nociceptive pathways. Nevertheless, many questions remain to be answered. More particularly, there is insufficient data on the role of sex hormones in men and the correct dosing according to sex differences, hormonal changes and comorbidities. The above remains a major challenge for future development.https://doi.org/10.1186/s10194-023-01557-6ProlactinOxytocinMigrainePainPRLROTR |
| spellingShingle | Anna K. Szewczyk Samiye Ulutas Tülin Aktürk Linda Al-Hassany Corinna Börner Federica Cernigliaro Michalis Kodounis Salvatore Lo Cascio David Mikolajek Dilara Onan Chiara Ragaglini Susanna Ratti Eduardo Rivera-Mancilla Sofia Tsanoula Rafael Villino Karl Messlinger Antoinette Maassen Van Den Brink Tessa de Vries on behalf of the European Headache Federation School of Advanced Studies (EHF-SAS) Prolactin and oxytocin: potential targets for migraine treatment The Journal of Headache and Pain Prolactin Oxytocin Migraine Pain PRLR OTR |
| title | Prolactin and oxytocin: potential targets for migraine treatment |
| title_full | Prolactin and oxytocin: potential targets for migraine treatment |
| title_fullStr | Prolactin and oxytocin: potential targets for migraine treatment |
| title_full_unstemmed | Prolactin and oxytocin: potential targets for migraine treatment |
| title_short | Prolactin and oxytocin: potential targets for migraine treatment |
| title_sort | prolactin and oxytocin potential targets for migraine treatment |
| topic | Prolactin Oxytocin Migraine Pain PRLR OTR |
| url | https://doi.org/10.1186/s10194-023-01557-6 |
| work_keys_str_mv | AT annakszewczyk prolactinandoxytocinpotentialtargetsformigrainetreatment AT samiyeulutas prolactinandoxytocinpotentialtargetsformigrainetreatment AT tulinakturk prolactinandoxytocinpotentialtargetsformigrainetreatment AT lindaalhassany prolactinandoxytocinpotentialtargetsformigrainetreatment AT corinnaborner prolactinandoxytocinpotentialtargetsformigrainetreatment AT federicacernigliaro prolactinandoxytocinpotentialtargetsformigrainetreatment AT michaliskodounis prolactinandoxytocinpotentialtargetsformigrainetreatment AT salvatorelocascio prolactinandoxytocinpotentialtargetsformigrainetreatment AT davidmikolajek prolactinandoxytocinpotentialtargetsformigrainetreatment AT dilaraonan prolactinandoxytocinpotentialtargetsformigrainetreatment AT chiararagaglini prolactinandoxytocinpotentialtargetsformigrainetreatment AT susannaratti prolactinandoxytocinpotentialtargetsformigrainetreatment AT eduardoriveramancilla prolactinandoxytocinpotentialtargetsformigrainetreatment AT sofiatsanoula prolactinandoxytocinpotentialtargetsformigrainetreatment AT rafaelvillino prolactinandoxytocinpotentialtargetsformigrainetreatment AT karlmesslinger prolactinandoxytocinpotentialtargetsformigrainetreatment AT antoinettemaassenvandenbrink prolactinandoxytocinpotentialtargetsformigrainetreatment AT tessadevries prolactinandoxytocinpotentialtargetsformigrainetreatment AT onbehalfoftheeuropeanheadachefederationschoolofadvancedstudiesehfsas prolactinandoxytocinpotentialtargetsformigrainetreatment |